PF-Atlas › Clinical Trials › NCT02989168

Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

GBT440 · Phase 2

Registry ID

NCT02989168

Phase

Phase 2

Status

Terminated

Drug / intervention

GBT440

Sponsor

Global Blood Therapeutics

Start

2016-11

Enrollment

Locations

About this trial

This is an open label study in which eligible IPF subjects who are using supplemental oxygen at rest will receive GBT440 orally daily.

View NCT02989168 on ClinicalTrials.gov →

Explore related

All GBT440 trials All IPF trials

Related trials

GBT440 — NCT02846324

Medical disclaimer. This page summarizes public trial data for NCT02989168 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.